share_log

Guggenheim Initiates Coverage On Aerovate Therapeutics With Buy Rating, Announces Price Target of $36

Guggenheim Initiates Coverage On Aerovate Therapeutics With Buy Rating, Announces Price Target of $36

古根海姆以买入评级开始对Aerovate Therapeutics进行报道,宣布目标价为36美元
Benzinga ·  2023/03/01 05:27

Guggenheim analyst Vamil Divan initiates coverage on Aerovate Therapeutics (NASDAQ:AVTE) with a Buy rating and announces Price Target of $36.

古根海姆分析师Vamil Divan以买入评级启动Aerovate治疗公司(纳斯达克:AVTE)的报道,并宣布目标价为36美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发